Dr. Anna Sala and Míriam Garcia to attend the European meeting of the HARRIER RTH258-C002 clinical trial

Dr. Anna Sala, the ophthamologist specialising in retina, together with Míriam Garcia, the study coordinator and optometrist at the Institut de la Màcula, are to attend the meeting of researchers and coordinators of the HARRIER RTH258-C002 trial. The meeting will take place in Frankfurt on 15-17 October.

All the study researchers and coordinators will take part in the meeting, where data from Phase II of the RTH258 trial and details about the innovative study will be shared. This will be the first collaborative project between Alcon and Novartis Pharma and is therefore an opportunity to pool contents from all the working groups. The project’s success lies in this feedback between institutions.

HARRIER is a clinical trial in Phase III that assesses the efficacy and safety of RTH258 6mg administered through intravitreal injections in patients with choroidal neovascularisation secondary to Age-Related Macular Degeneration (AMD) in comparison to the administration of aflibercept (EYLEA®).

Visit the link for further information.